| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 344 | 2023 |
| Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium CH van der Wouden, A Cambon‐Thomsen, E Cecchin, KC Cheung, ... Clinical Pharmacology & Therapeutics 101 (3), 341-358, 2017 | 328 | 2017 |
| Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for … S Björkman, A Folkesson, S Jönsson European journal of clinical pharmacology 65, 989-998, 2009 | 204 | 2009 |
| Developmental pharmacokinetics of ciclosporin–a population pharmacokinetic study in paediatric renal transplant candidates S Fanta, S Jönsson, JT Backman, MO Karlsson, K Hoppu British journal of clinical pharmacology 64 (6), 772-784, 2007 | 92 | 2007 |
| Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms S Fanta, M Niemi, S Jönsson, MO Karlsson, C Holmberg, PJ Neuvonen, ... Pharmacogenetics and genomics 18 (2), 77-90, 2008 | 87 | 2008 |
| Population pharmacokinetics of ethambutol in South African tuberculosis patients S Jönsson, A Davidse, J Wilkins, JS Van der Walt, USH Simonsson, ... Antimicrobial agents and chemotherapy 55 (9), 4230-4237, 2011 | 86 | 2011 |
| A diagnostic tool for population models using non-compartmental analysis: the ncappc package for R C Acharya, AC Hooker, GY Türkyılmaz, S Jönsson, MO Karlsson Computer methods and programs in biomedicine 127, 83-93, 2016 | 70 | 2016 |
| Handling interoccasion variability in model‐based dose individualization using therapeutic drug monitoring data JA Abrantes, S Jönsson, MO Karlsson, EI Nielsen British journal of clinical pharmacology, 2019 | 64 | 2019 |
| Kinetics of methylmercury and inorganic mercury in lactating and nonlactating mice J Sundberg, S Jönsson, MO Karlsson, IP Hallén, A Oskarsson Toxicology and applied pharmacology 151 (2), 319-329, 1998 | 53 | 1998 |
| Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study S Jönsson, USH Simonsson, R Miller, MO Karlsson The Journal of Clinical Pharmacology 55 (11), 1268-1279, 2015 | 51 | 2015 |
| Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study CH van der Wouden, S Böhringer, E Cecchin, KC Cheung, ... Pharmacogenetics and genomics 30 (6), 131-144, 2020 | 42 | 2020 |
| Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization A Brekkan, E Berntorp, K Jensen, EI Nielsen, S Jönsson Journal of Thrombosis and Haemostasis 14 (4), 724-732, 2016 | 42 | 2016 |
| Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED S Jönsson, MC Kjellsson, MO Karlsson Journal of pharmacokinetics and pharmacodynamics 31, 299-320, 2004 | 36 | 2004 |
| Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients AW Oosten, JA Abrantes, S Jönsson, P de Bruijn, EJM Kuip, A Falcão, ... European journal of clinical pharmacology 72, 459-467, 2016 | 34 | 2016 |
| Toxicokinetics of lead in lactating and nonlactating mice IP Hallén, S Jönsson, MO Karlsson, A Oskarsson Toxicology and applied pharmacology 136 (2), 342-347, 1996 | 34 | 1996 |
| Population pharmacokinetics of edoxaban in patients with symptomatic deep‐vein thrombosis and/or pulmonary embolism—the Hokusai‐VTE phase 3 study R Niebecker, S Jönsson, MO Karlsson, R Miller, J Nyberg, EHJ Krekels, ... British Journal of Clinical Pharmacology 80 (6), 1374-1387, 2015 | 33 | 2015 |
| Long‐term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism S Fanta, S Jönsson, MO Karlsson, M Niemi, C Holmberg, K Hoppu, ... The Journal of Clinical Pharmacology 50 (5), 581-597, 2010 | 33 | 2010 |
| Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice J Sundberg, S Jönsson, MO Karlsson, A Oskarsson Toxicology and applied pharmacology 154 (2), 160-169, 1999 | 33 | 1999 |
| Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ... NeuroImage 61 (4), 849-856, 2012 | 32 | 2012 |
| A rational approach for selection of optimal covariate‐based dosing strategies S Jönsson, MO Karlsson Clinical Pharmacology & Therapeutics 73 (1), 7-19, 2003 | 31 | 2003 |
Mats KarlssonUppsala UniversityEmail confirmado em farmaci.uu.se